Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 229

Sort by

Sort Order Select

Journal Articles

Central Line-Associated Thrombus Formation in an Inhibitor Negative Severe Hemophilia A Patient on Emicizumab

Nicholas B George, MD, Alexander Paschke, Katie Scott, MD

Blood (2019) 134 (Supplement_1): 4938.

https://doi.org/10.1182/blood-2019-127105

Published: 2019

Journal Articles

Prothrombin Complex Concentrate in the Management of Major Bleeding Induced By Oral Anticoagulant Therapy: Experience of a Tertiary Care Center

Mohammed Abdullah Alsheef, MD, Abdul Rehman Z. Zaidi, MBBS, Ghaydaa Juma Kullab, MD

Blood (2019) 134 (Supplement_1): 4967.

https://doi.org/10.1182/blood-2019-126740

Published: 2019

Journal Articles

Novel Pathogenic Genes and Rare Mutations of Congenital Factor V Deficiency: A Case Report

Haixia Guo, MD PhD

Blood (2019) 134 (Supplement_1): 4920.

https://doi.org/10.1182/blood-2019-126350

Published: 2019

Journal Articles

An Institutional Survey of Warfarin Reversal in the Setting of Life-Threatening Bleeds

Ian Garrahy, DO, Tushar Pawar, MD MPH, Anthony Donato, MD, Amber Stevenson, CMA, Daniel Forman, DO

Blood (2019) 134 (Supplement_1): 4981.

https://doi.org/10.1182/blood-2019-129065

Published: 2019

Journal Articles

Determining the Approximate Factor VIII Level Equivalency of Patients with Severe Hemophilia A on Emicizumab Using Global Hemostasis Assays

Hande Kizilocak, Elizabeth Marquez-Casas, BS, Jemily Malvar, MS, Roxana Carmona, MD, Guy Young, MD

Blood (2019) 134 (Supplement_1): 1134.

https://doi.org/10.1182/blood-2019-123820

Published: 2019

Journal Articles

Estimating the Risk of Myocardial Infarction in Persons with Hemophilia A Using a Machine-Learning Approach with US Claims Data

Imi Faghmous, MPH, Carlos Flores, MPH, Kati Sarouei, MD, Tiffany Y. Chang, MD MAS, Anisha M. Patel, PhD, Cami S. Sima, MD, Peter Kuebler, PharmD

Blood (2019) 134 (Supplement_1): 1133.

https://doi.org/10.1182/blood-2019-123761

Published: 2019

Journal Articles

Low-Grade Inflammation in Hemophilia

Lynn M Knowles, PhD, Hermann Eichler, Jan Pilch, MD

Blood (2019) 134 (Supplement_1): 1115.

https://doi.org/10.1182/blood-2019-125127

Published: 2019

Journal Articles

Evaluation of the in Vitro Procoagulant Effect of Factor IX Concentrates in Patients on Prophylaxis with Emicizumab

Ihosvany Fernandez-Bello, María Teresa Alvarez Román, Mónica Martín, María Isabel Rivas Pollmar, Sara García Barcenilla, Carmen García Martínez, Tamara Cebanu, Paula Acuña, Raul Justo Sanz, Elena Monzón Manzano, Miguel A Canales, MD PhD, Nora Butta, PhD, Victor Jimenez-Yuste

Blood (2019) 134 (Supplement_1): 1118.

https://doi.org/10.1182/blood-2019-129983

Published: 2019

Journal Articles

Evaluation of a Next-Generation FVIII Mimetic Antibody, Mim8, in Combination with Recombinant FVIIa, FVIII and Activated Prothrombin Complex Concentrate

Laurent Burnier, PhD, Mette B Hermit, PhD, Ida Hilden, Mirella Ezban, PhD, Stine L Kjellev, PhDDVM

Blood (2019) 134 (Supplement_1): 2388.

https://doi.org/10.1182/blood-2019-123340

Published: 2019

Journal Articles

Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with >18 Months' Follow-up in the FEIBA Global Outcome Study (FEIBA GO)

Jerzy Windyga, Pal A Holme, C. Hermans, Ana R Cid, Nirjhar Chatterjee, Hongyu Jiang, Viridiana Cano-Garcia, Carmen Escuriola

Blood (2019) 134 (Supplement_1): 2418.

https://doi.org/10.1182/blood-2019-124324

Published: 2019

Journal Articles

Comparison of Bypassing Agents in Patients on Emicizumab Using Global Hemostasis Assays

Hande Kizilocak, Elizabeth Marquez-Casas, BS, Jemily Malvar, MS, Roxana Carmona, MD, Guy Young, MD

Blood (2019) 134 (Supplement_1): 904.

https://doi.org/10.1182/blood-2019-132050

Published: 2019

Journal Articles

Thrombin Generation Assay in Plasma from Hemophilia a Patients with or without Inhibitors on Concizumab Prophylaxis: Spiking with rFVIIa or aPCC

Marianne Kjalke, PhD, Mads Kjelgaard-Hansen, Søren Andersen, Ida Hilden

Blood (2019) 134 (Supplement_1): 3639.

https://doi.org/10.1182/blood-2019-122301

Published: 2019

Journal Articles

Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and "Work Around" By PCCs

Genmin Lu, Joyce P. Lin, BS, Khanh Bui, BS, John T. Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2019) 134 (Supplement_1): 713.

https://doi.org/10.1182/blood-2019-124864

Published: 2019

Journal Articles

Evaluation of a Fixed, Low-Dose Four-Factor Prothrombin Complex Concentrate Dosing Protocol for International Normalized Ratio Reversal at Two Academic Medical Centers

Kathryn Dane, PharmD, John Lindsley, PharmD, Satish Pramod Shanbhag, MBBS, MPH, Michael B. Streiff, MD

Blood (2019) 134 (Supplement_1): 3386.

https://doi.org/10.1182/blood-2019-131404

Published: 2019

Journal Articles

Severe Bleeding Events in Hemophilia Α Patients Receiving Emicizumab Prophylaxis

Karen L. Zimowski, MD, Glaivy M. Batsuli, MD, Paulette Bryant, MD, Jenny McDaniel, MD, Kelly Tickle, MSN, APN, PPCNP-BC, Shannon L. Meeks, MD, Robert F. Sidonio, Jr., MD MSc

Blood (2019) 134 (Supplement_1): 1126.

https://doi.org/10.1182/blood-2019-126659

Published: 2019

Journal Articles

The Frequency and Effect of Baseline Cross-Reacting and De Novo Inhibitors to Recombinant Porcine FVIII in Patients with Congenital and Acquired Hemophilia a

Carolyne Elbaz, MD, Katerina Pavenski, MD, Hina Chaudhry, BSc, Jerome M. Teitel, MD FRCPC, Michelle Sholzberg, MDBSc,FRCPC,MSc

Blood (2019) 134 (Supplement_1): 1128.

https://doi.org/10.1182/blood-2019-122260

Published: 2019

Journal Articles

Pharmacoeconomic Analysis of Ideal Vs. Actual Body Weight-Based Treatment for Adult Persons with Hemophilia Α

Ming Y. Lim, MBBChir,MA, Jeffrey A. Gilreath, PharmD, Paul F. Bray, MD, George M. Rodgers, MD PhD

Blood (2019) 134 (Supplement_1): 4684.

https://doi.org/10.1182/blood-2019-121679

Published: 2019

Journal Articles

Treatment of rare factor deficiencies other than hemophilia

Marzia Menegatti, Flora Peyvandi

Blood (2019) 133 (5): 415–424.

https://doi.org/10.1182/blood-2018-06-820738

Published: 2019

Journal Articles

Saskatoon Urban Hospital Frozen Plasma Utilization and Appropriateness Audit

Jennifer E Leung, MD, Heather Panchuk, Oksana C. Prokopchuk-Gauk, MDBSc

Blood (2018) 132 (Supplement 1): 5074.

https://doi.org/10.1182/blood-2018-99-114176

Published: 2018

Journal Articles

Maintaining Perioperative Hemostasis in Patients with Severe Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis

Karen L. Zimowski, MD, Glaivy M. Batsuli, MD, Mark T. Reding, MD, Jatin Rana, MD, Michael U. Callaghan, MD, Kelly Tickle, MSN, APN, PPCNP-BC, Shannon L. Meeks, MD, Robert F. Sidonio, Jr., MD

Blood (2018) 132 (Supplement 1): 635.

https://doi.org/10.1182/blood-2018-99-115089

Published: 2018

NARROW

Central Line-Associated Thrombus Formation in an Inhibitor Negative Severe Hemophilia A Patient on Emicizumab

Prothrombin Complex Concentrate in the Management of Major Bleeding Induced By Oral Anticoagulant Therapy: Experience of a Tertiary Care Center

Novel Pathogenic Genes and Rare Mutations of Congenital Factor V Deficiency: A Case Report

An Institutional Survey of Warfarin Reversal in the Setting of Life-Threatening Bleeds

Determining the Approximate Factor VIII Level Equivalency of Patients with Severe Hemophilia A on Emicizumab Using Global Hemostasis Assays

Estimating the Risk of Myocardial Infarction in Persons with Hemophilia A Using a Machine-Learning Approach with US Claims Data

Low-Grade Inflammation in Hemophilia

Evaluation of the in Vitro Procoagulant Effect of Factor IX Concentrates in Patients on Prophylaxis with Emicizumab

Evaluation of a Next-Generation FVIII Mimetic Antibody, Mim8, in Combination with Recombinant FVIIa, FVIII and Activated Prothrombin Complex Concentrate

Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with >18 Months' Follow-up in the FEIBA Global Outcome Study (FEIBA GO)

Comparison of Bypassing Agents in Patients on Emicizumab Using Global Hemostasis Assays

Thrombin Generation Assay in Plasma from Hemophilia a Patients with or without Inhibitors on Concizumab Prophylaxis: Spiking with rFVIIa or aPCC

Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and "Work Around" By PCCs

Evaluation of a Fixed, Low-Dose Four-Factor Prothrombin Complex Concentrate Dosing Protocol for International Normalized Ratio Reversal at Two Academic Medical Centers

Severe Bleeding Events in Hemophilia Α Patients Receiving Emicizumab Prophylaxis

The Frequency and Effect of Baseline Cross-Reacting and De Novo Inhibitors to Recombinant Porcine FVIII in Patients with Congenital and Acquired Hemophilia a

Pharmacoeconomic Analysis of Ideal Vs. Actual Body Weight-Based Treatment for Adult Persons with Hemophilia Α

Treatment of rare factor deficiencies other than hemophilia

Saskatoon Urban Hospital Frozen Plasma Utilization and Appropriateness Audit

Maintaining Perioperative Hemostasis in Patients with Severe Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only